Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis

References

• Husby G, Marhaug G, Dowtor B, et al. Serum amyloid a (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1994;1(2):119–137. doi:10.3109/13506129409148635.
   Web of Science ®Google Scholar
• Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesisand targeted therapy. Annu Rev Pathol. 2015;10:321–344. doi:10.1146/annurev-pathol-020712-163913.
   PubMed Web of Science ®Google Scholar
• Gursky O. Structural basis for vital function and malfunction of serum amyloid A: an Acute-Phase protein that wears hydrophobicity on its sleeve. Curr Atheroscler Rep. 2020;22(11):69. doi:10.1007/s11883-020-00888-y.
   PubMed Web of Science ®Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265(2):501–523. doi:10.1046/j.1432-1327.1999.00657.x.
   PubMedGoogle Scholar
• Brunger AF, Nienhuis HLA, Bijzet J, et al. Causes of AA amyloidosis: a systematic review. Amyloid. 2020;27(1):1–12. doi:10.1080/13506129.2019.1693359.
   PubMed Web of Science ®Google Scholar
• Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002;440(2):111–122. doi:10.1007/s00428-001-0582-9.
   PubMed Web of Science ®Google Scholar
• Blank N, Hegenbart U, Lohse P, et al. Risk factors for AA amyloidosis in Germany. Amyloid. 2015;22(1):1–7. doi:10.3109/13506129.2014.980942.
   PubMed Web of Science ®Google Scholar
• Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525–532. doi:10.1111/bjh.12286.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Försti A, et al. Incidence of hereditary amyloidosis and autoinflammatory diseases in Sweden: endemic and imported diseases. BMC Med Genet. 2013;14:88. doi:10.1186/1471-2350-14-88.
   PubMed Web of Science ®Google Scholar
• Westermark P, Nilsson GT. Demonstration of amyloid protein AA in old museum specimens. Arch Pathol Lab Med. 1984;108(3):217–219.
   PubMed Web of Science ®Google Scholar
• Zschiesche W, Jakob W. Pathology of animal amyloidoses. Pharmacol Ther. 1989;41(1-2):49–83. doi:10.1016/0163-7258(89)90102-2.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Westermark P. Serum amyloid a and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583(16):2685–2690. doi:10.1016/j.febslet.2009.04.026.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–2371. doi:10.1056/NEJMoa070265.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137–143. doi:10.3109/14397595.2013.854048.
   PubMed Web of Science ®Google Scholar
• Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012;142:w13580. doi:10.4414/smw.2012.13580.
   PubMed Web of Science ®Google Scholar
• Sayed RH, Hawkins PN, Lachmann HJ. Emerging treatments for amyloidosis. Kidney Int. 2015;87(3):516–526. doi:10.1038/ki.2014.368.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for alzheimer’s disease. Nat Med. 1995;1(2):143–148. doi:10.1038/nm0295-143.
   PubMed Web of Science ®Google Scholar
• Elimova E, Kisilevsky R, Szarek WA, et al. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. Faseb J. 2004;18(14):1749–1751. doi:10.1096/fj.03-1436fje.
   PubMedGoogle Scholar
• Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356(23):2349–2360. doi:10.1056/NEJMoa065644.
   PubMed Web of Science ®Google Scholar
• Rumjon A, Coats T, Javaid MM. Review of eprodisate for the treatment of renal disease in AA amyloidosis. Int J Nephrol Renovasc Dis. 2012;5:37.
   PubMedGoogle Scholar
• Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585–603. doi:10.1016/j.rdc.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Liepnieks JJ, Wang L, et al. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol. 1999;155(1):123–133. doi:10.1016/S0002-9440(10)65107-3.
   PubMed Web of Science ®Google Scholar
• Puscalau-Girtu I, Scheller JS, Claus S, et al. Cell assay for the identification of amyloid inhibitors in systemic AA amyloidosis. Amyloid. 2019;26(1):24–33. doi:10.1080/13506129.2019.1568978.
   PubMed Web of Science ®Google Scholar
• Lundmark K, Shariatpanahi AV, Westermark GT. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLoS One. 2013;8(11):e79104. doi:10.1371/journal.pone.0079104.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Yokota T, Kawano H, et al. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A Pathol Anat Histopathol. 1989;415(5):411–419. doi:10.1007/BF00747742.
   PubMedGoogle Scholar
• Shirahama T, Miura K, Ju ST, et al. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest. 1990;62(1):61–68.
   PubMed Web of Science ®Google Scholar
• Claus S, Meinhardt K, Aumüller T, et al. Cellular mechanism of fibril formation from serum amyloid A1 protein. EMBO Rep. 2017;18(8):1352–1366. doi:10.15252/embr.201643411.
   PubMed Web of Science ®Google Scholar
• Shirahama T, Cohen AS. Intralysosomal formation of amyloid fibrils. Am J Pathol. 1975;81:101.
   PubMed Web of Science ®Google Scholar
• Kollmer M, Meinhardt K, Haupt C, et al. Electron tomography reveals the fibril structure and lipid interactions in amyloid deposits. Proc Natl Acad Sci U S A. 2016;113(20):5604–5609. doi:10.1073/pnas.1523496113.
   PubMed Web of Science ®Google Scholar
• Claus S, Puscalau-Girtu I, Walther P, et al. Cell-to-cell transfer of SAA1 protein in a cell culture model of systemic AA amyloidosis. Sci Rep. 2017;7(1):45683. doi:10.1038/srep45683.
   PubMedGoogle Scholar
• Forssmann W-G, Schulz-Knappe P, Meyer M, et al. Peptide chemistry 1992 : proceedings of the 2nd Japan Symposium on Peptide Chemistry November 9-13, 1992, Shizuoka, Japan. ESCOM; 1993.
   Google Scholar
• Schulz-Knappe P, Schrader M, Ständker L, et al. Peptide bank generated by large-scale preparation of circulating human peptides. J Chromatogr A. 1997;776(1):125–132. doi:10.1016/s0021-9673(97)00152-0.
   PubMed Web of Science ®Google Scholar
• Münch J, Ständker L, Forssmann WG, et al. Discovery of modulators of HIV-1 infection from the human peptidome. Nat Rev Microbiol. 2014;12(10):715–722. 2014;12:doi:10.1038/nrmicro3312.
   PubMed Web of Science ®Google Scholar
• Eberle J, Wiehe RS, Gole B, et al. A fibrinogen alpha fragment mitigates Chemotherapy-Induced MLL rearrangements. Front Oncol. 2021;11:689063. doi:10.3389/fonc.2021.689063.
   PubMed Web of Science ®Google Scholar
• Brauer F, Schmidt K, Zahn RC, et al. A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob Agents Chemother. 2013;57(2):679–688. doi:10.1128/AAC.01152-12.
   PubMed Web of Science ®Google Scholar
• Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem. 1989;182(2):319–326. doi:10.1016/0003-2697(89)90602-7.
   PubMed Web of Science ®Google Scholar
• Dopler A, Guntau L, Harder MJ, et al. Self versus nonself discrimination by the soluble complement regulators factor H and FHL-1. J Immunol. 2019;202(7):2082–2094. doi:10.4049/jimmunol.1801545.
   PubMed Web of Science ®Google Scholar
• Frank R. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron. 1992;48(42):9217–9232. doi:10.1016/S0040-4020(01)85612-X.
   Web of Science ®Google Scholar
• Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367–1372. doi:10.1038/nbt.1511.
   PubMed Web of Science ®Google Scholar
• Wu Z, Roberts DS, Melby JA, et al. MASH explorer: a universal software environment for Top-Down proteomics. J Proteome Res. 2020;19(9):3867–3876. doi:10.1021/acs.jproteome.0c00469.
   PubMed Web of Science ®Google Scholar
• Niedermeyer THJ, Strohalm M. mMass as a software tool for the annotation of cyclic peptide tandem mass spectra. PLoS One. 2012;7(9):e44913. doi:10.1371/journal.pone.0044913.
   PubMed Web of Science ®Google Scholar
• Ragland SA, Criss AK. From bacterial killing to immune modulation: recent insights into the functions of lysozyme. PLoS Pathog. 2017;13(9):e1006512. doi:10.1371/journal.ppat.1006512.
   PubMed Web of Science ®Google Scholar
• Bruinsma IB, Karawajczyk A, Schaftenaar G, et al. A rational design to create hybrid β-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-β. Medchemcomm. 2011;2(1):60–64. doi:10.1039/C0MD00213E.
   Web of Science ®Google Scholar
• Tjernberg LO, Näslund J, Lindqvist F, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271(15):8545–8548. doi:10.1074/jbc.271.15.8545.
   PubMed Web of Science ®Google Scholar
• Soto C, Kindy MS, Baumann M, et al. Inhibition of alzheimer’s amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996;226(3):672–680. doi:10.1006/bbrc.1996.1413.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. 1993;362(6420):553–557. 1993;362:doi:10.1038/362553a0.
   PubMed Web of Science ®Google Scholar
• Anker S, Hinderhofer K, Baur J, et al. Lysozyme amyloidosis—a report on a large german cohort and the characterisation of a novel amyloidogenic lysozyme gene variant. Amyloid. 2022;29(4):245–254. doi:10.1080/13506129.2022.2072198.
   PubMed Web of Science ®Google Scholar
• Canet D, Last AM, Tito P, et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat Struct Biol. 2002;9(4):308–315. doi:10.1038/nsb768.
   PubMedGoogle Scholar
• Vettore N, Moray J, Brans A, et al. Characterisation of the structural, dynamic and aggregation properties of the W64R amyloidogenic variant of human lysozyme. Biophys Chem. 2021;271:106563. doi:10.1016/j.bpc.2021.106563.
   PubMed Web of Science ®Google Scholar
• Morozova-Roche LA, Zurdo J, Spencer A, et al. Amyloid fibril formation and seeding by Wild-Type human lysozyme and its Disease-Related mutational variants. J Struct Biol. 2000;130(2-3):339–351. doi:10.1006/jsbi.2000.4264.
   PubMed Web of Science ®Google Scholar
• Luo J, Wärmländer SKTS, Gräslund A, et al. Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer’s disease. Chem Commun (Camb). 2013;49(58):6507–6509. doi:10.1039/c3cc42325e.
   PubMed Web of Science ®Google Scholar
• Luo J, Wärmländer SKTS, Gräslund A, et al. Non-chaperone proteins can inhibit aggregation and cytotoxicity of alzheimer amyloid β peptide. J Biol Chem. 2014;289(40):27766–27775. doi:10.1074/jbc.M114.574947.
   PubMed Web of Science ®Google Scholar
• Brouwer J, van Leeuwen-Herberts T, de Ruit M V Determination of lysozyme in serum, urine, cerebrospinal fluid and feces by enzyme immunoassay. Clin Chim Acta. 1984;142(1):21–30. doi:10.1016/0009-8981(84)90097-4.
   PubMed Web of Science ®Google Scholar
• Torsteinsdóttir I, Håkansson L, Hällgren R, et al. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology. 1999;38(12):1249–1254. doi:10.1093/rheumatology/38.12.1249.
   PubMed Web of Science ®Google Scholar
• Gordon S, Todd J, Cohn ZA. In vitro synthesis and secretion of lysozyme by mononuclear phagocytes. J Exp Med. 1974;139(5):1228–1248. doi:10.1084/jem.139.5.1228.
   PubMed Web of Science ®Google Scholar